Cargando…

Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma

Although many efforts have recently contributed to improve our knowledge of molecular pathogenesis of multiple myeloma (MM), the role and significance of long non-coding RNAs (lncRNAs) in plasma cells (PC) malignancies remains virtually absent. To this aim, we developed a custom annotation pipeline...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ronchetti, Domenica, Agnelli, Luca, Taiana, Elisa, Galletti, Serena, Manzoni, Martina, Todoerti, Katia, Musto, Pellegrino, Strozzi, Francesco, Neri, Antonino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924754/ https://www.ncbi.nlm.nih.gov/pubmed/26895470 http://dx.doi.org/10.18632/oncotarget.7442

Ejemplares similares

A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2018)

Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2020)

Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma
por: Todoerti, Katia, et al.
Publicado: (2021)

In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2016)

LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?
por: Taiana, Elisa, et al.
Publicado: (2020)

Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing
por: Agnelli, Luca, et al.
Publicado: (2019)

DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome
por: Todoerti, Katia, et al.
Publicado: (2021)

Long Non-Coding RNAs in Multiple Myeloma
por: Nobili, Lucia, et al.
Publicado: (2018)

Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2022)

Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity
por: Todoerti, Katia, et al.
Publicado: (2021)

lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome
por: Ronchetti, D, et al.
Publicado: (2016)

Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs
por: D’Aquila, Patrizia, et al.
Publicado: (2021)

Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins
por: Taiana, Elisa, et al.
Publicado: (2022)

Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients
por: Calura, Enrica, et al.
Publicado: (2015)

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
por: Lionetti, Marta, et al.
Publicado: (2015)

Long non-coding RNAs in B-cell malignancies: a comprehensive overview
por: Nobili, Lucia, et al.
Publicado: (2017)

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
por: Amodio, Nicola, et al.
Publicado: (2018)

Notch signaling deregulation in multiple myeloma: A rational molecular target
por: Colombo, Michela, et al.
Publicado: (2015)

The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma
por: Ronchetti, D, et al.
Publicado: (2012)

P847: BIOLOGICAL AND MOLECULAR CHARACTERIZATION OF IN SILICO IDENTIFIED PUTATIVE INHIBITORS OF PARASPECKLE ASSEMBLY WITH POTENTIAL ANTI-MULTIPLE MYELOMA ACTIVITY.
por: Traini, Valentina, et al.
Publicado: (2023)

Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine
por: Simeon, Vittorio, et al.
Publicado: (2015)

An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2008)

A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias
por: Lionetti, Marta, et al.
Publicado: (2015)

Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature
por: Lionetti, Marta, et al.
Publicado: (2016)

Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche
por: Colombo, Michela, et al.
Publicado: (2016)

IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts
por: Bolzoni, Marina, et al.
Publicado: (2017)

P849: DEPLETION OF DIS3 IN MULTIPLE MYELOMA LEADS TO PERTURBATION IN RNA METABOLISM, CELL CYCLE PROGRESSION AND MITOTIC CHECKPOINT.
por: Favasuli, V., et al.
Publicado: (2022)

Genomic Instability in Multiple Myeloma: A “Non-Coding RNA” Perspective
por: Taiana, Elisa, et al.
Publicado: (2021)

The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer
por: Cusenza, Vincenza Ylenia, et al.
Publicado: (2023)

P875: ACTIVATION OF LNCRNA NEAT1 LEADS TO SURVIVAL ADVANTAGE OF MULTIPLE MYELOMA CELLS BY SUPPORTING A REGULATORY LOOP WITH DNA REPAIR PROTEINS: RATIONAL BASES FOR NEAT1 THERAPEUTIC TARGETING IN THE DISEASE
por: Taiana, E., et al.
Publicado: (2022)

Aberrant lncRNA Expression in Multiple Myeloma
por: Meng, Hui, et al.
Publicado: (2018)

Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
por: Lionetti, Marta, et al.
Publicado: (2021)

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
por: Paradzik, Tina, et al.
Publicado: (2021)

Notch signaling drives multiple myeloma induced osteoclastogenesis
por: Colombo, Michela, et al.
Publicado: (2014)

Impact of Host Genes and Strand Selection on miRNA and miRNA* Expression
por: Biasiolo, Marta, et al.
Publicado: (2011)

NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome
por: Ronchetti, Domenica, et al.
Publicado: (2020)

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
por: Botta, Cirino, et al.
Publicado: (2021)

Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma
por: Gelli, Elisa, et al.
Publicado: (2023)

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2021)

The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma
por: Platonova, Natalia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6erold022hg0iufecm0smim184